Clinical Trial Update: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a quadruple regimen of daratumumab, bortezomib, cyclophosphamide, and dexamethasone for Monoclonal Gammopathy of Renal Si…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Renal Significance

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Monoclonal Gammopathy of Renal Significance | Phase 2 | Status: RECRUITING